Managing treatment-experienced pediatric and adolescent Hiv patients: Role of darunavir

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 595-615

  Neely, Michael ^a   Kovacs, Andrea ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adolescent; Child; Darunavir; Protease inhibitors; Treatment

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIARRHYTHMIC AGENT; ATAZANAVIR; CARBAMAZEPINE; CLARITHROMYCIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DESIPRAMINE; DIDANOSINE; DIGOXIN; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; RALTEGRAVIR; RANITIDINE; RIFABUTIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDEX EC; VORICONAZOLE; WARFARIN; ZIDOVUDINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL DREAMING; ACUTE HEPATITIS; ACUTE PANCREATITIS; ADOLESCENT DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANOREXIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; CHOLESTEROL BLOOD LEVEL; COUGHING; DIABETES MELLITUS; DIARRHEA; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEVER; FLATULENCE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MYALGIA; NAUSEA; NEUTROPHIL COUNT; PANCREATITIS; PILL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SALVAGE THERAPY; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; VOMITING;

EID: 77949448099     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Joint United Nations Programme on HIV/AIDS. 2008 Report on the global AIDS epidemic. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/ 2008/2008-Global-report.asp. Accessed April 29, 2009.
2. Malhotra A, Gaur S, Whitley-Williams P, Loomis C, Petrova A. Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study. AIDS Res Ther. 2007;4:15.
3. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009. http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf. Accessed April 2, 2009.
4. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81(24):13845-13851.
5. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49(6):2314-2321.
6. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47(10):3123-3129.
7. 21CFR201.57(a)(c)(9)(iv)(A). http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?fr=201.57. AccessedApril 6, 2009.
8. Bologna R, Rugina S, Cahn P, et al. Safety and Efficacy of Darunavir Co-administered with Low-dose Ritonavir in Treatment-experienced Children and Adolescents at Week 24. In: Program and Abstracts, 15th Conference on Retroviruses and Opportunistic Infections; 2008: abstract 78LB. http://www.retroconference.org/2008/Abstracts/33380.htm. Accessed March 16, 2009.
9. Sekar V, Van de Casteele T, Van Beelan B, et al. Dose selection and pharmacokinetics-pharmacodynamics (PK-PD) of darunavir coadministered with low-dose ritonavir (DRV/r) in the DELPHI (TMC114-C212) trial in treatment-experienced, HIV-1-infected children and adolescents. In: Program and Abstracts, 17th International AIDS Conference; 2008:abstract TUPE0078. http://www.iasociety.org/Default.aspx?pageId=1 1&abstractId=200713841. Accessed March 23, 2009.
10. Blanche S, Bologna R, Cahn P, et al. 48-wk Safety and efficacy of darunavir/ritonavir (DRV/r) in treatment-experienced children and adolescents in DELPHI. In: Program and Abstracts, ICAAC/IDSA 2008; abstract H-894.
11. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol. 2007;47:479-484.
12. Prezista [US Package Insert]. http://www.prezista.com. Accessed March 23, 2009.
13. Vermeir M, Lachau-Durand S, Mannens G, et al. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos. 2009;37(4):809-820.
14. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.
15. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389-1397.
16. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008;42(7):1048-1059.
17. Viganò A, Meroni L, Marchetti G, et al. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. Antivir Ther. 2008;13(6):839-843.
18. Guidance for Industry-Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. http://www.fda.gov/cder/guidance/3647fnl.htm. Accessed April 1, 2009.
19. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178.
20. Molina J, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46(1):24-31.
21. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother. 2007;60:885-888.
22. Picchio G, Vangeneugden T, Van Baelen B, et al. Prior utilization or resistance to amprenavir at screening has minimal effect on the 48-Week response to darunavir/r in the POWER 1, 2, and 3 studies. In: Program and Abstracts, 14th Conference on Retroviruses and Opportunistic Infections; 2007:abstract 609.
23. Picchio G, De Meyer S, de Bethune MP. Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients". AIDS. 2008;22:165-167.
24. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49-58.
25. Chen TK, Aldrovandi GM. Review of HIV antiretroviral drug resistance. Pediatr Infect Dis J. 2008;27(8):749-752.
26. Vermeiren H, Van Craenenbroeck E, Alen P, et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods. 2007;145(1):47-55.
27. Hoefnagel JGM, Koopmans PP, Burger DM, Schuurman R, Galama JMD. Role of the inhibitory quotient in HIV therapy. Antivir Ther. 2005;10(8):879-892.
28. De Meyer S, Dierynck I, Lathouwers E, et al. Phenotypic and genotypic determinants of resistance to daruanvir: analysis of data from treatment-experienced patients in POWER 1,2,3 and DUET-1 and 2. Antivir Ther. 2008;13 Suppl 3:A33.
29. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008;16(5):138-145.
30. Winters B, Vermeiren H, Van Craenenbroeck E, et al. Development of Virco® TYPE resistance analysis, including clinical cut-offs, for TMC114. In: Program and Abstracts, 15th International HIV Drug Resistance Workshop; 2006; abstract 160.
31. de Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24(3):379-388.
32. Pellegrin I, Wittkop L, Joubert LM, et al. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther. 2008;13(2):271-279.
33. Delaugerre C, Pavie J, Palmer P, et al. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. AIDS. 2008;22(14):1809-1813.
34. Spagnuolo V, Gianotti N, Seminari E, et al. Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients. J Acquir Immune Defic Syndr. 2009;50(2):192-195.
35. Lambert-Niclot S, Flandre P, Canestri A, et al. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother. 2008;52:491-496.
36. virco TYPE HIV-1 Clinical Cut-offs. http://www.vircolab.com. Accessed March 16, 2009.
37. PhenoSense HIV for reverse transcriptase and protease inhibitors assay. http://www.monogrambio.com. Accessed March 16, 2009.
38. Sekar V, De Meyer S, Vangeneugden T, et al. Pharmacokinetic/ parmacodynamic analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients. In: Program and Abstracts, 13th Conference on Retroviruses and Opportunistic Infections; 2003; abstract 639b.
39. Moltó J, Santos JR, Pérez-Alvarez N, et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008;52(11):3928-3932.
40. Konigs C, Feiterna-Sperling C, Esposito S, et al. Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive. In: Program and Abstracts, 16th Conference on Retroviruses and Opportunistic Infections; 2009; abstract 879.
41. TMC125-TiDP35-C213: Safety and antiviral activity of etravirine (TMC125) in treatment-experienced, HIV infected children and adolescents. http://www.clinicaltrials.gov/ct2/show/NCT00665847? term=intelence&rank=11. Accessed April 6, 2009.
42. Larrú B, Resino S, Bellón JM, et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. J Antimicrob Chemother. 2008;61(1):183-190.
43. Resino S, Bellón JM, Muñoz-Fernández MA. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J Antimicrob Chemother. 2006;57(3):579-582.
44. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir- ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368(9534):476-482.
45. Quercia R, Garnier E, Ferré V, et al. Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up. HIV Clin Trials. 6(2):73-80.
46. Salazar JC, Cahn P, Yogev R, et al. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS. 2008;22(14):1789-1798.
47. Aptivus Prescribing Information. http://www.aptivus.us/patient/index.jsp. Accessed April 7, 2009.
48. Cohan D, Feakins C, Wara D, et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS. 2005;19(9):989-990.
49. Desai N, Mathur M. Selective transmission of multidrug resistant HIV to a newborn related to poor maternal adherence. Sex Transm Infect. 2003;79(5):419-421.
50. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008. p 1-139. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 21, 2009.
51. Darunavir: Summary of Product Characteristics. http://www.emea.europa.eu/ . Accessed March 23, 2009.
52. Sekar VJ, De Pauw M, Mariën K, et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther (Lond). 2007;12(4):509-514.
53. Sekar VJ, Lefebvre E, Mariën K, et al. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. Ther Drug Monit. 2007;29(6):795-801.
54. Sekar VJ, Lefebvre E, De Marez T, et al. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs R D. 2007;8:241-248.
55. Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;51(3):958-961.
56. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol. 2008;48(1):60-65.
57. Sekar VJ, Lefebvre E, De Pauw M, Vangeneugden T, Hoetelmans RM. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol. 2008;66(2):215-221.
58. Sekar VJ, Lefebvre E, Guzman SS, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther. 2008;13(4):563-569.
59. Sekar V, Lefebvre E, De Marez T, et al. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin Drug Investig. 2008;28(8):479-485.